logo-loader

IXICO PLC

Receive alerts
Market:
AIM
Market Cap:
£30.25 m
Price
64.50 GBX
Change
5.74%
52 weeks high
66.05
52 weeks low
18.78

In brief

IXICO’s TrialTracker® platform and Artificial Intelligence (AI) software algorithms are used by the global pharmaceutical industry to collate and interpret brain scan data from MRI and positron emission tomography (PET) scanners, as well as to make sense of real-world data collected using wearable biosensors.  Our specialist data analytics services identify and measure unique biomarkers from brain scan and wearable biosensor data produced in clinical research programmes.  The results we deliver support our clients in their clinical decisions to align patient selection, protect patient safety and assess disease progression and drug efficacy. 

Our neuroimaging and digital biomarkers are powering some of the most important clinical trials in neuroscience today.  IXICO is also collaborating with partners and developing new analytical techniques and companion digital health products to impact patient outcomes.

Deep dive We explore the investor case for growth companies

Snapshot

  • Provides data analytics services to interpret brain scans
  • AI-based algorithms aid neurological disease trials
  • Order book has risen to £21.2mln
  • First profit just booked